New Study Says I Was Wrong About NMN and NR?

Key Takeaways

• Small study favors NR, larger trial finds no difference
• Gut microbes convert NR and NMN to nicotinic acid
• NAD increase does not translate into clear clinical benefits
• Exercise remains cheaper way to support NAD metabolism
• Some NR/NMN absorption still occurs intact

Pulse Analysis

The NAD‑boosting supplement market has been driven by a rivalry between nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), each touted as the superior precursor for cellular energy. Early animal work and a handful of small human trials created a narrative that NR could raise NAD 2.3‑fold more than NMN, fueling premium pricing and aggressive marketing. However, a recent Nature Metabolism study involving 65 participants demonstrated that both molecules double circulating NAD after two weeks, with no statistically significant difference. This larger, rigorously designed trial undermines the claim that one compound outperforms the other in humans.

Beyond the headline numbers, mechanistic research is reshaping our understanding of how oral NR and NMN are processed. Multiple isotope‑labeling and ex‑vivo fecal studies reveal that gut microbiota rapidly convert these molecules into nicotinic acid, which then feeds the Preiss‑Handler pathway to regenerate NAD. Even when administered intravenously, a substantial fraction re‑enters the enterohepatic circuit, exposing it again to microbial conversion. While a minor portion may be absorbed intact, the dominant route appears to be microbe‑mediated, suggesting that the perceived superiority of either supplement may be a red herring.

Clinically, the story is less promising. Meta‑analyses of randomized trials in older adults show no meaningful gains in muscle strength, gait speed, or metabolic markers despite confirmed NAD elevation. A long‑COVID trial similarly reported no symptom improvement with NR supplementation. These outcomes imply that simply raising systemic NAD is insufficient for functional benefit, at least in the studied populations. For investors, clinicians, and consumers, the evidence points toward focusing on proven lifestyle interventions—particularly regular exercise—which naturally supports NAD homeostasis without the cost or uncertainty associated with high‑priced NR or NMN products.